Marco A. Chacón, Ph.D. – Founder, CEO & President

Dr. Chacón is the founder, president and CEO of Paragon Bioservices, Incorporated. With 30+ years of research laboratory experience and 20 years of executive experience, Dr. Chacón has the depth of experience, energy and personal commitment to transform biotech startups to commercially-viable enterprises.

He is also the founder of Irazu Biodiscovery in 2000, based on his research and scientific insights regarding the mechanism of calorie-restriction protection.  Dr. Chacón holds a Ph.D. in Nutritional Sciences from the University of Maryland.

Robert Eberwein – VP, GMP Manufacturing 

Mr. Eberwein joined Paragon in 2007 and brings over 25 years of biopharmaceutical manufacturing experience and knowledge to Paragon. Prior to joining Paragon, Mr. Eberwein spent eight years as the head of GMP manufacturing at Cambrex producing a variety of bulk biologics for use in Phase I through Phase III clinical trials as well as commercial launch.

He began his career in the Frederick Cancer Research Facility (Fort Detrick) spending 11 years in microbial fermentation and natural products isolation/purification. From there, he continued his work in protein and vaccine production at companies such as Becton Dickinson, North American Vaccine and Cambrex Baltimore, a contract manufacturing organization. Mr. Eberwein obtained a B.A. in Biology from Hood College in Frederick, Maryland.

Ronald A. J. Wilson – CFO

Mr. Wilson has over 35 years of financial accounting and tax experience. He is a former partner of KPMG and Ernst & Young, having worked in New York, Paris, Boston and Baltimore specializing in private and small public technology companies. Mr. Wilson is a graduate of Harvard College (BA, 1966) and New York University (MS-Accounting, 1972). His Board roles have included Avedis Zildjian Company, Combined Health Agencies (Board Chair) and the Greater Baltimore Technology Council (Treasurer).